Skip to main content
Top
Published in: BMC Oral Health 1/2024

Open Access 01-12-2024 | Lichen Planus | Research

The effect of antiresorptive therapy on the prevalence and severity of oral lichen planus: a retrospective study

Authors: Puria Parvini, Karina Obreja, Emilio A. Cafferata, Tuba Aini, Yanislava Lermen, Amira Begic, Robert Sader, Frank Schwarz

Published in: BMC Oral Health | Issue 1/2024

Login to get access

Abstract

Background

Antiresorptive therapy (AR) disrupts osseous homeostasis and can induce direct irritation over the gastrointestinal mucosa; however, its possible erosive effects on the oral epithelium have not been totally described. Among the most frequent oral erosive lesions, oral lichen planus (OLP) frequently presents as painful mucosal ulcerations, arising from basal membrane inflammatory damage. Thus, the aim of this retrospective study was to describe the association between AR and the incidence of OLP.

Methods

This case-control study included data from 148 patients (17 patients undergoing AR therapy (AR group) / 131 without AR therapy (Control group)). Each patient record was systematically processed and the association between AR drugs and OLP clinical characteristics within both groups was assessed.

Results

The erosive form of OLP was significantly more frequent in the AR group than in the Control group (p = 0.029). Indeed, the AR treatment using alendronic acid (41.2%) was the most frequently reported. Additionally, the erosive form of OLP showed the strongest association with pain and burning sensation among the OLP types (p < 0.050). However, disease worsening and AR consumption were not significantly associated (p = 0.150).

Conclusions

Patients under AR therapy show more clinical symptoms associated to the erosive type of OLP. Regardless of the AR therapy, the erosive type of OLP is associated with more severe symptoms.
Appendix
Available only for authorised users
Literature
2.
go back to reference Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.CrossRefPubMed Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.CrossRefPubMed
6.
go back to reference Kharazmi M, Persson U, Warfvinge G. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. J Oral Maxillofac Surg. 2012;70(12):2793–7.CrossRefPubMed Kharazmi M, Persson U, Warfvinge G. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. J Oral Maxillofac Surg. 2012;70(12):2793–7.CrossRefPubMed
10.
go back to reference Khammissa RAG, Chandran R, Masilana A, Lemmer J, Feller L. Adverse immunologically mediated oral mucosal reactions to systemic medication: lichenoid tissue reaction/interface dermatitis-stomatitis, autoimmune vesiculobullous disease, and ige-dependent and immune complex reactions. J Immunol Res. 2018;2018:10. https://doi.org/10.1155/2018/7645465. PMID: 29984259; PMCID: PMC6015680.CrossRef Khammissa RAG, Chandran R, Masilana A, Lemmer J, Feller L. Adverse immunologically mediated oral mucosal reactions to systemic medication: lichenoid tissue reaction/interface dermatitis-stomatitis, autoimmune vesiculobullous disease, and ige-dependent and immune complex reactions. J Immunol Res. 2018;2018:10. https://​doi.​org/​10.​1155/​2018/​7645465. PMID: 29984259; PMCID: PMC6015680.CrossRef
12.
go back to reference Sugerman PB, Savage NW. Oral lichen planus: causes, diagnosis and management. Aust Dent J. 2002;47(4):290–7.CrossRefPubMed Sugerman PB, Savage NW. Oral lichen planus: causes, diagnosis and management. Aust Dent J. 2002;47(4):290–7.CrossRefPubMed
13.
go back to reference Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46(2):207–14.CrossRefPubMed Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46(2):207–14.CrossRefPubMed
14.
go back to reference Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):72–80.CrossRefPubMed Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):72–80.CrossRefPubMed
15.
go back to reference El-Howati A, Thornhill MH, Colley HE, Murdoch C. Immune mechanisms in oral lichen planus. Oral Dis. 2022;29(4):1400–15. El-Howati A, Thornhill MH, Colley HE, Murdoch C. Immune mechanisms in oral lichen planus. Oral Dis. 2022;29(4):1400–15.
17.
go back to reference Papamitsou T, Fotiadou S, Papachristodoulou A, Dietrich EM, Kamperis D, Toskas A, et al. Effect of alendronic acid on buccal mucosa. J Dent Oral Health. 2018;4(3):0116. Papamitsou T, Fotiadou S, Papachristodoulou A, Dietrich EM, Kamperis D, Toskas A, et al. Effect of alendronic acid on buccal mucosa. J Dent Oral Health. 2018;4(3):0116.
18.
go back to reference Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: a report of the American Dental Association. J Am Dent Assoc. 2017;148(10):712–e727710.CrossRefPubMed Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: a report of the American Dental Association. J Am Dent Assoc. 2017;148(10):712–e727710.CrossRefPubMed
19.
go back to reference Matthews JB, Scully CM, Potts AJ. Oral lichen planus: an immunoperoxidase study using monoclonal antibodies to lymphocyte subsets. Br J Dermatol. 1984;111(5):587–95.CrossRefPubMed Matthews JB, Scully CM, Potts AJ. Oral lichen planus: an immunoperoxidase study using monoclonal antibodies to lymphocyte subsets. Br J Dermatol. 1984;111(5):587–95.CrossRefPubMed
20.
go back to reference Calabresi V, Carrozzo M, Cozzani E, et al. Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin Immunol. 2007;122(2):207–13.CrossRefPubMed Calabresi V, Carrozzo M, Cozzani E, et al. Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin Immunol. 2007;122(2):207–13.CrossRefPubMed
21.
go back to reference Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol. 1968;25(1):31–42.CrossRefPubMed Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol. 1968;25(1):31–42.CrossRefPubMed
22.
go back to reference Silverman S Jr. Oral lichen planus: a potentially premalignant lesion. J Oral Maxillofac Surg. 2000;58(11):1286–8.CrossRefPubMed Silverman S Jr. Oral lichen planus: a potentially premalignant lesion. J Oral Maxillofac Surg. 2000;58(11):1286–8.CrossRefPubMed
23.
go back to reference Shi P, Liu W, Zhou ZT, He QB, Jiang WW. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev. 2010;19:844–9.CrossRefPubMed Shi P, Liu W, Zhou ZT, He QB, Jiang WW. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev. 2010;19:844–9.CrossRefPubMed
24.
25.
go back to reference Gonzalez-Moles MA, Warnakulasuriya S, Gonzalez-Ruiz I, et al. Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis. Oral Dis. 2021;27(4):813–28.CrossRefPubMed Gonzalez-Moles MA, Warnakulasuriya S, Gonzalez-Ruiz I, et al. Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis. Oral Dis. 2021;27(4):813–28.CrossRefPubMed
26.
go back to reference Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc. 2014;145(1):45–56.CrossRefPubMed Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc. 2014;145(1):45–56.CrossRefPubMed
27.
go back to reference Idrees M, Kujan O, Shearston K, Farah CS. Oral lichen planus has a very low malignant transformation rate: a systematic review and meta-analysis using strict diagnostic and inclusion. J Oral Pathol Med. 2021;50:287–98.CrossRefPubMed Idrees M, Kujan O, Shearston K, Farah CS. Oral lichen planus has a very low malignant transformation rate: a systematic review and meta-analysis using strict diagnostic and inclusion. J Oral Pathol Med. 2021;50:287–98.CrossRefPubMed
29.
go back to reference Garcia-Font M, Curco N, Prat C, Vives P. [Mouth sores caused by alendronate]. Actas Dermosifiliogr. 2009;100(1):77–8.PubMed Garcia-Font M, Curco N, Prat C, Vives P. [Mouth sores caused by alendronate]. Actas Dermosifiliogr. 2009;100(1):77–8.PubMed
30.
go back to reference Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66(5):839–47. PMID: 18423269; PMCID: PMC2426967.CrossRefPubMedPubMedCentral Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66(5):839–47. PMID: 18423269; PMCID: PMC2426967.CrossRefPubMedPubMedCentral
31.
go back to reference Dietrich E-M, Theodora P, Antonia S, Georgios K, Esthelle N. Ultrastructural alterations of the inferior alveolar nerve in wistar rats after alendronate administration per os: hypothesis for the generation of the “numb chin syndrome”. J Histol Histopathol. 2015;2:24. http://dx.doi.org/10.7243/2055-091X-2-24.CrossRef Dietrich E-M, Theodora P, Antonia S, Georgios K, Esthelle N. Ultrastructural alterations of the inferior alveolar nerve in wistar rats after alendronate administration per os: hypothesis for the generation of the “numb chin syndrome”. J Histol Histopathol. 2015;2:24. http://​dx.​doi.​org/​10.​7243/​2055-091X-2-24.CrossRef
32.
go back to reference Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58(10):519–37.PubMed Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58(10):519–37.PubMed
33.
go back to reference Li C, Tang X, Zheng X, et al. Global prevalence and incidence estimates of oral lichen planus: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(2):172–81.CrossRefPubMedPubMedCentral Li C, Tang X, Zheng X, et al. Global prevalence and incidence estimates of oral lichen planus: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(2):172–81.CrossRefPubMedPubMedCentral
35.
go back to reference Garcia-Pola MJ, Gonzalez-Alvarez L, Garcia-Martin JM. Treatment of oral lichen planus. Systematic review and therapeutic guide. Med Clin (Barc). 2017;149(8):351–62.PubMed Garcia-Pola MJ, Gonzalez-Alvarez L, Garcia-Martin JM. Treatment of oral lichen planus. Systematic review and therapeutic guide. Med Clin (Barc). 2017;149(8):351–62.PubMed
Metadata
Title
The effect of antiresorptive therapy on the prevalence and severity of oral lichen planus: a retrospective study
Authors
Puria Parvini
Karina Obreja
Emilio A. Cafferata
Tuba Aini
Yanislava Lermen
Amira Begic
Robert Sader
Frank Schwarz
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2024
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-024-04331-5

Other articles of this Issue 1/2024

BMC Oral Health 1/2024 Go to the issue